Max Planck Study Demonstrates Utility of HCS And Functional Genomics in Target ID Efforts | GenomeWeb

Combining RNAi-based functional genomic screens with automated high-content image analysis of cells could become a new way for drug companies to identify novel targets, according to a recent study.

Earlier this month, researchers led by Marino Zerial, a director at the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany, and their collaborators published a paper in Nature using this approach to study the role of human kinases in endocytosis [Nature, Vol. 436, 7 July 2005, p. 78-86].

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.